Выбор редакции

EntreMed ([[ENMD]] +4.4%) pops after submitting a new drug global clinical trial application with the China Food and Drug Administration for its oncology drug candidate, ENMD-2076. The purpose of the application is to expand Phase 2 clinical trials in advanced/metastatic sarcoma currently being conducted at Princess Margaret Hospital. CEO Dr. Ken Ren notes that expanding trials into China will enable the [[ENMD]] to explore the drug's potential at an accelerated pace, due to faster patient recruitment and lower study costs.

EntreMed (ENMD +4.4%) pops after submitting a new drug global clinical trial application with the China Food and Drug Administration for its oncology drug candidate, ENMD-2076. The purpose of the application is to expand Phase 2 clinical trials in advanced/metastatic sarcoma currently being conducted at Princess Margaret Hospital. CEO Dr. Ken Ren notes that expanding trials into China will enable the ENMD to explore the drug's potential at an accelerated pace, due to faster patient recruitment and lower study costs. Post your comment!

НОВОСТИ ПО ТЕМЕ